{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT00613964: Phase 4 Interventional Terminated Heart Failure
(2009)
Source URL:
Class:
PROTEIN
Carperitide is a synthetic, recombinant atrial natriuretic peptide with both vasodilating and diuretic activity that was developed by Asubio Pharma and used in Japan for acute heart failure treatment. Although the current Japanese Society of Cardiology guidelines for treatment of acute heart failure (AHF) make a class IIa recommendation for Carperitide, a recent meta-analysis and retrospective study revealed that Carperitide could not improve survival rates and was rather associated with a more than double in-hospital mortality rate in patients with AHF.
Status:
Possibly Marketed Outside US
Source:
NCT01041040: Phase 4 Interventional Completed Acute Myeloblastic Leukemia
(2007)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00560690: Phase 4 Interventional Completed Hepatitis C
(2007)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01147042: Phase 4 Interventional Terminated IFN-Gamma Therapy
(2010)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Japan:Nartograstim (Genetical Recombination)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00390897: Phase 4 Interventional Completed Chronic Myeloid Leukaemia
(2003)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01704001: Phase 4 Interventional Completed Disseminated Intravascular Coagulation
(2012)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00121433: Phase 4 Interventional Completed Healthy
(2004)
Source URL:
Class:
PROTEIN
